The present invention relates to stable novel oral formulation of Palonosetron which melts in mouth and hence easy to swallow. Further, the present invention relates to process for the preparation of such formulation of Palonosetron.

The present invention relates to a method for preparation of a stable lyophilized azacitidine composition with reduced levels of impurity.

This present invention relates to stable pharmaceutical composition of fingolimod or its pharmaceutical!;/ acceptable salts thereof and process for preparation of the same. The pharmaceutical compositions as disclosed in the present invention can be dispensed as an oral dosage form, which are bioequivalent to the ma...

The present invention relates to a stable pharmaceutical composition comprising Fesoterodine or pharmaceutically acceptable salt thereof, amorphous hydrated silicon dioxide and other suitable pharmaceutically acceptable excipients; wherein process for preparation of a stable pharmaceutical composition comprising ste...

The present invention relates to a stable pharmaceutical composition of Tigecycline and process for the preparation of the same. The composition comprises Tigecycline and maltose wherein the pH of the bulk solution or solution after reconstitution is in between 3 - 6.

The present invention relates to stable pharmaceutical compositions of Tadalafil for oral administration comprising tadalafil particles having D90 particle si/.e greater than about 40 μm and one or more pharmaceutically acceptable excipienls, Further the present invention also discloses the process for the preparati...

The present invention relates to a stable palonosetron injection comprising palonosetron or a pharmaceutically acceptable salt thereof as active ingredient for preventing and/or reducing emesis. In particular, the present invention relates to a stable palonosetron injection, wherein the pH of the injection is less ...

This present invention relates to modified release pharmaceutical composition of memantine or its pharmaceutical!)" acceptable salts thereof and process for preparation of the same. The invention is particularly suitable for once-a-day solid oral pharmaceutical dosage forms, possessing improved formulation character...

The present invention relates to process for the preparation of stable lyophilized Decitabine injection composition having reduced amount of impurity. Also present invention relates a process for minimizing the vial to vial variation of impurity.

The present invention relates to stable lyophilized Bendamustine composition having better impurity profile. Further, the present invention relates to process for the preparation of such stable lyophilized Bendamustine composition which is easy to reconstitute.

N/A

This invention relates to process to obtain stable lyophilized composition by lowering the pH during solution phase before lyophilization without addition of an acid or buffer during preparation of composition.

The present invention relates to aceclofenac effervescent formulation in tablet, granule, powder form and method of preparation thereof. Formulation comprises 14.28% w/w aceclofenac; anhydrous citric acid 1.4-10% w/w, sodium glycine carbonate 14-80% w/w, polyvinylpyrrolidone 0.5-5% w/w, isopropyl alcohol 0.5-3% w/w,...

The present invention relates to pharmaceutical formulation of antiepileptic drug preferably oxcarbazepine. The formulation comprises multiple tablets or pellets of immediate release or controlled release nature, which are filled inside the capsule to provides drug effect for 24 hours and is suitable for once a day ...

The present invention relates to oral pharmaceutical dosage forms for acid labile benzimidazole compound preferably pantoprazole. This dosage form is in the form of capsule or tablets containing the said benzimidazole.

The present invention relates to non aqueous pharmaceutical preparations containing gemcitabine or its pharmaceutically acceptable salts in the form of ready-to-use solutions wherein the concentration of Gemcitabine is in the range of about 16 mg/ml to about 200 mg/ml and a pH of about 3.5 to 10.0. Further, a method...

Controlled release oral composition of muscarinic receptor antagonist, in solid form, for treatment of unstable or over active bladder comprising an active core of muscarinic receptor antagonist that is coated by a functional coat wherein an active core and functional coat are optionally disjoined by seal coat. ...

N/A

The present invention relates to an in-vitro method for measuring the T75 of reduction kinetics of iron from Fe+3 to Fe+2 in an iron-sucrose complex and hence assessing the bioequivalency of iron-sucrose composition. According to the method as per the present invention, T75 of reduction kinetics of iron in an iron-s...

Once a day sustained release solid oral dosage form of phenothiazine derivative preferably the dibenzothiazepine derivative and their pharmaceutially acceptable salts comprising of a channelizer, rate controlling polymer and suitable pharmaceutically acceptable excipients. The formulation of the present invention is...

The present invention relates to a stabilized pharmaceutical composition comprising pravastatin or its pharmaceutically acceptable salts along with suitable adjuvants. This composition is stable at acidic pH environment of the gastric lumina. The invention also relates to a process for making the pharmaceutical comp...

The present invention relates to a stable oral dosage formulation comprising HMG-CoA reductase inhibitor preferably Fluvastatin and its pharmaceutically acceptable salt which provides sustained drug action suitable for once a day administration.

The present invention relates to a modified composition of calcitriol. The pharmaceutical composition comprises of calcitriol, calcium salt and zinc and/or their substitutes. Further this relates to the process for preparation of stabilized pharmaceutical compositions resulting therefrom. This dosage form is palatab...

The present invention discloses a stable ready-to-use aqueous pharmaceutical preparation containing Cetrorelix or its pharmaceutically acceptable salt, wherein the preparation does not contain any surfactant. Further, the present invention discloses process for the preparation of said stable ready-to-use aqueous pha...

The present invention describes a stable composition of Temsirolimus for parenteral administration. The said composition includes anti-oxidant and alcoholic solvent, wherein the pH of the composition is below 5.0. The said composition may also further include a chelating agent and / or a surfactant- Further, the pre...

Present" invention relates to once a day modified release pharmaceutical composition of Clozapine comprising of total polymer content not more than 30 wt% and further optionally comprises of coating; wherein 40 to 60% of the active ingredient is released by immediate release.

The present invention relates to stable methotrexate injection comprising methotrexate or a pharmaceutically acceptable salt thereof as active ingredient. In particular, the present invention relates to stable methotrexate injection, wherein the methotrexate is present in a pharmaceutically acceptable solvent at a c...

This present invention relates to sustained release pharmaceutical composition of Agomelatine. The invention is particularly suitable for once-a-day solid oral pharmaceutical dosage forms which release therapeutically effective amount of the active ingredient over an extended time period. Further, the present invent...